Core Insights - Johnson & Johnson's innovative targeted drug, Lico® (lanzetini mesylate tablets), has been launched online on JD Health, providing a breakthrough treatment option for a large population of lung cancer patients in China [1][2] - The drug is used in combination with evan monoclonal antibody for first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), offering significant overall survival benefits and safety advantages [1] - JD Health aims to enhance the accessibility of this innovative treatment through its "first station for new specialty drugs" capabilities, ensuring more lung cancer patients can benefit from it [1] Industry Context - According to the 2024 National Cancer Report, there are 1.06 million new lung cancer patients annually in China, with approximately 85% being non-small cell lung cancer [1] - The mutation rate of the EGFR gene, the most common driver gene in NSCLC, is about 50%, indicating a high demand for more effective and safer innovative treatment options [1] - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson's Innovative Pharmaceuticals to leverage JD Health's supply chain and service capabilities alongside Johnson & Johnson's innovative drug portfolio in oncology and other key disease areas [1]